WebMar 16, 2024 · CAMBRIDGE - Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, today announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from … WebMar 21, 2024 · Explanatory Note. On March 1, 2024, Enliven Therapeutics, Inc. (the “ Company ”) filed a Current Report on Form 8-K (the “ Initial Form 8-K ”) to report, among other things, the completion of a previously announced merger pursuant to which Iguana Merger Sub, Inc. merged with and into Enliven Inc. (formerly, Enliven Therapeutics, …
Statement of Ownership (sc 13g)
WebCo-founder, Chief Executive Officer, and Member of the Board of Directors. Joe Lyssikatos, PhD. Co-founder, Chief Scientific Officer, and Member of the Board of Directors. Anish Patel, PharmD. Co-founder and Chief Operating Officer. Helen Collins, MD. Chief Medical Officer. Ben Hohl. Chief Financial Officer. Web19 hours ago · The Investor Relations website contains information about Enliven Therapeutics's business for stockholders, potential investors, and financial analysts. gerry ford presidency
3 Stocks in the Limelight on New Analyst Coverage
WebApr 13, 2024 · According to 9 analysts, the average rating for ELVN stock is "Buy." The 12-month stock price forecast is $32.64, which is an increase of 69.56% from the latest price. WebCompany profile page for Enliven Therapeutics Inc/CO including stock price, company news, press releases, executives, board members, and contact information WebNovel Insights,Precision Therapeutics. We are developing kinase inhibitors that enhance efficacy through better selectivity and combinability, combat resistance, address brain … gerry frewin